<span>How lab data enables more accurate patient coding for value-based care success</span>
February 7, 2025

How lab data enables more accurate patient coding for value-based care success

As the healthcare landscape continues to evolve, value-based care is playing a pivotal role in enhancing patient outcomes while effectively managing costs. For providers engaged in value-based care programs, accurate patient coding isn’t just important—it's essential for achieving success. Unfortunately, many ACOs and Medicare Advantage networks face significant challenges due to coding inaccuracies, which can hinder their progress toward performance goals and cost savings. In this blog, Labcorp's Brian Buesing, Vice President of commercial efforts for large physician organizations and value-based care networks, explores how integrating robust laboratory data can streamline coding practices and ultimately lead to better health outcomes and financial performance.
Read more »
January 17, 2025

Fast-tracking inhalation toxicology testing for the global market

Labcorp's expertise in inhalation toxicology and end-to-end early phase development solutions (EPDS) enabled a leading Japanese pharmaceutical company to fast-track the global development of a novel inhaled large-molecule drug. With plans to commercialize in various geographies across the world, the company needed a lab partner with specialized inhalation capabilities and global reach. Labcorp's extensive inhalation toxicology expertise, including experience with non-human primate models, positioned them as the ideal testing partner. Their EPDS team provided customized guidance and seamless coordination to accelerate the program. Through high-touch partnership and local representatives, Labcorp delivered tailored support that met the client's specific needs and challenges. This case study illustrates how Labcorp helped their client capitalize on the growing inhaled drug market and advance an important new therapy globally.
Read more »
January 17, 2025

In vitro chromosomal aberration assay: Unraveling the genetic puzzle to evaluate medical device safety at Labcorp’s Bedford Genetic Toxicology Laboratory

Genotoxicity testing is crucial for medical device safety. Labcorp's chromosomal aberration assay meticulously evaluates chromosomes to determine if a device causes genotoxic harm. This powerful tool assesses potential risks early in development, enabling manufacturers to mitigate risks before commercialization. The scientists at the GeneTox Laboratory in Bedford, Massachusetts, understand the intricacies of this test and offer it to sponsors for the evaluation of their medical devices, one chromosome at a time.
Read more »